BVNRY - Bavarian Nordic receives $120m contract for manufacturing of smallpox and mpox vaccine from U.S. government
2023-08-03 11:36:25 ET
- Bavarian Nordic A/S ( OTCPK:BVNRY ) shares up nearly 5% on Thursday after it received $120M contract from the U.S. Government for manufacturing of smallpox and mpox vaccine.
- The order, representing $96M of the contract value, will be manufactured and invoiced in 2023 and will only partly restore the inventory, which was used to manufacture vaccines in response to the mpox outbreak in 2022.
- In addition, Bavarian Nordic will manufacture and supply additional liquid-frozen doses of the vaccine in 2023, valued at $3M.
- Bavarian Nordic has worked with the U.S. government on the development, manufacturing and supply of a non-replicating smallpox vaccine since 2003.
- Source: Press Release
For further details see:
Bavarian Nordic receives $120m contract for manufacturing of smallpox and mpox vaccine from U.S. government